Our Pricing

How to Switch From Wegovy to Mounjaro: Clinical Guidance for UK Patients

Many patients considering a Wegovy to Mounjaro switch are looking for improved weight loss outcomes or better tolerability profiles. As a UK-registered pharmacy with thousands of weight management patients under care, we've supported numerous successful transitions between these GLP-1 medications. This guide provides the clinical framework our prescribers use when facilitating switches from semaglutide to tirzepatide therapy.

Why Patients Consider a Wegovy to Mounjaro Switch

The decision to switch from Wegovy to Mounjaro typically stems from three clinical scenarios our prescribers encounter regularly. First, patients who have plateaued on Wegovy 1.7mg or higher doses may seek the dual-agonist mechanism of tirzepatide for additional weight loss potential. The SURPASS-2 trial demonstrated that tirzepatide 15mg produced superior weight reduction compared to semaglutide 1mg, with average losses of 12.4kg versus 6.2kg respectively over 40 weeks[1].

Second, some patients experience persistent gastrointestinal side effects on Wegovy that may improve with Mounjaro's different receptor activity profile. Whilst both medications affect GLP-1 receptors, tirzepatide's additional GIP agonism can alter the side effect profile in ways that benefit certain individuals[2]. Third, cost considerations drive switches, particularly when Mounjaro pricing becomes more competitive than Wegovy for equivalent therapeutic outcomes.

Our clinical team evaluates each switch request individually, considering your current Wegovy dose, weight loss trajectory, side effect history, and treatment goals. Not every patient requires a switch - those responding well to Wegovy with minimal side effects often continue their current therapy. However, for patients meeting specific clinical criteria, transitioning to Mounjaro can offer renewed progress towards weight management targets.

Clinical Protocol for Wegovy to Mounjaro Switch Timing

The pharmacokinetic profile of semaglutide requires careful consideration when planning your Wegovy to Mounjaro switch timeline. Semaglutide has a half-life of approximately 7 days, meaning it takes roughly 4-5 weeks to fully clear from your system[3]. However, our prescribers don't typically recommend waiting for complete clearance before initiating Mounjaro.

The standard protocol we follow involves administering your first Mounjaro dose one week after your final Wegovy injection. This timing balances two priorities: avoiding a gap in GLP-1 receptor stimulation that could trigger rebound appetite, whilst minimising overlapping drug exposure that might intensify gastrointestinal effects. If you're currently on Wegovy 1.7mg, you'll typically start Mounjaro at the 2.5mg initiation dose, regardless of your Wegovy dose level.

Some patients worry about 'starting over' with the lower Mounjaro dose, but this graduated approach significantly reduces side effect risk during the transition period. The tirzepatide dose escalation schedule (2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg) allows your body to adapt to the dual-agonist mechanism whilst maintaining therapeutic effect from residual semaglutide levels during the first few weeks.

Managing the Transition Week

The week between your last Wegovy dose and first Mounjaro injection represents a critical transition period. Our pharmacists recommend maintaining consistent meal timing and composition during this week to avoid appetite fluctuations. Stay well-hydrated and monitor for any return of hunger signals, which typically remain suppressed due to residual semaglutide activity. If you experience concerning symptoms during this transition week, our clinical team is available for guidance before you administer your first Mounjaro dose.

Expected Outcomes When Switching From Wegovy to Mounjaro

Patients completing a Wegovy to Mounjaro switch often ask what weight loss outcomes they should anticipate. Clinical trial data provides useful benchmarks, though individual results vary considerably. In the SURPASS-2 head-to-head trial, participants switching to tirzepatide after previous GLP-1 RA therapy achieved meaningful additional weight reduction, though not as dramatic as treatment-naïve patients[1].

During your first 12 weeks on Mounjaro following the switch, expect a continuation of gradual weight loss rather than the accelerated losses sometimes seen in treatment-naïve patients. The SURPASS trials showed that tirzepatide's weight loss effect accumulates over 40-72 weeks, with many patients achieving their maximum benefit between months 9-12[4]. Your previous Wegovy therapy has already addressed some of the initial rapid weight loss phase, so post-switch expectations should focus on steady progress towards your goal weight.

Side effect profiles during the Wegovy to Mounjaro switch vary by individual. Some patients report reduced nausea compared to their Wegovy experience, whilst others notice similar or slightly increased gastrointestinal effects during the first 4-6 weeks. These typically resolve as you adapt to tirzepatide's mechanism. Our prescribers recommend the same side effect management strategies used during initial Wegovy titration: smaller, more frequent meals, adequate hydration, and avoiding high-fat foods during the adaptation period.

Wegovy to Mounjaro Switch Prescription Process at Cured Pharmacy

Obtaining your Wegovy to Mounjaro switch prescription through Cured Pharmacy follows a streamlined clinical pathway designed by our superintendent pharmacist, Tarun Kumar (GPhC 2233073). The process begins with a comprehensive online assessment that captures your complete Wegovy treatment history, including doses used, duration of therapy, weight loss achieved, and any side effects experienced. This information allows our prescribers to make informed decisions about your suitability for switching.

Our UK-registered prescribers review every switch request individually, considering clinical guidelines from NICE and MHRA licensing conditions for tirzepatide. The assessment typically takes under 3 minutes to complete but provides our clinical team with the detailed information needed for safe prescribing. We'll ask about your current weight, BMI, any weight-related comorbidities, other medications you're taking, and your weight loss goals. This thorough approach ensures your Wegovy to Mounjaro switch is clinically appropriate and likely to benefit your overall health outcomes.

Once approved, your Mounjaro prescription is dispensed from our GPhC-registered pharmacy (9012511) with next-day delivery available across the UK. All medications are UK-licensed tirzepatide in the original manufacturer packaging. Your first order qualifies for £20 off using code Weightlossnew, bringing the price to £124.99. We provide complete dosing instructions, injection technique guidance, and access to our pharmacist support team throughout your treatment journey.

Ongoing Clinical Monitoring After Your Switch

Following your Wegovy to Mounjaro switch, our clinical team recommends monthly weight tracking and quarterly clinical reviews to assess treatment response. These check-ins allow our prescribers to optimise your dose escalation schedule and address any emerging concerns. We monitor for adequate weight loss (typically defined as 5% body weight reduction within 12 weeks of reaching therapeutic doses), side effect tolerability, and any changes in comorbid conditions like type 2 diabetes or hypertension that often improve with significant weight loss.

Cost Comparison: Wegovy to Mounjaro Switch Financial Considerations

The financial aspect of a Wegovy to Mounjaro switch represents a significant consideration for most patients, particularly those funding treatment privately. At Cured Pharmacy, Mounjaro starts from £124.99, with your first order eligible for £20 off using code Weightlossnew. This pricing structure makes the switch financially accessible whilst maintaining the quality standards expected from a UK-registered pharmacy.

When evaluating the cost-effectiveness of your Wegovy to Mounjaro switch, consider the complete treatment pathway rather than single-pen pricing. Tirzepatide's superior weight loss outcomes in clinical trials may allow some patients to reach their goal weight faster, potentially reducing the total treatment duration required[1]. However, individual responses vary, and our prescribers emphasise that medication choice should be driven primarily by clinical factors rather than cost alone.

Cured Pharmacy maintains transparent upfront pricing with no hidden consultation fees or subscription requirements. The price you see includes the medication, clinical assessment by a UK prescriber, and dispensing by our registered pharmacy team. We guarantee the lowest prices in the UK market, and our price-match commitment ensures you're receiving competitive value for your Wegovy to Mounjaro switch prescription.

Safety Considerations for Your Wegovy to Mounjaro Switch

Safety remains paramount when facilitating any medication switch, and the Wegovy to Mounjaro transition requires specific precautions. Both medications carry similar contraindications - personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and previous serious hypersensitivity to GLP-1 receptor agonists. If you developed any serious adverse reactions to Wegovy, our prescribers will carefully evaluate whether Mounjaro is appropriate[2].

The risk of hypoglycaemia increases if you're taking Mounjaro alongside other glucose-lowering medications, particularly insulin or sulphonylureas. During your Wegovy to Mounjaro switch assessment, inform our prescribers about all diabetes medications you're using. Dose adjustments to these concurrent therapies may be necessary to prevent low blood sugar episodes. Our clinical team provides specific guidance on blood glucose monitoring frequency during the transition period for patients with type 2 diabetes.

Gastrointestinal side effects represent the most common safety concern during the switch period. Whilst most patients tolerate the transition well, severe or persistent nausea, vomiting, or diarrhoea warrant clinical review. Our pharmacists are available to provide management strategies, but severe symptoms - particularly those causing dehydration or inability to tolerate oral intake - require medical assessment. We provide clear guidance on when to contact our clinical team versus when to seek urgent medical care during your Wegovy to Mounjaro switch journey.

Medication Interactions to Consider

Tirzepatide's effect on gastric emptying can alter the absorption of oral medications, similar to semaglutide's mechanism. If you take medications with narrow therapeutic windows - such as levothyroxine, warfarin, or certain antibiotics - inform our prescribers during your Wegovy to Mounjaro switch assessment. Timing adjustments or additional monitoring may be recommended to maintain therapeutic efficacy of these concurrent medications. Our pharmaceutical team provides personalised guidance on optimal medication scheduling to minimise interaction risks.

Scientific References

1. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., ... & SURPASS-2 Investigators. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503-515. [accessed 15 August 2026]
2. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. [accessed 15 August 2026]
3. Lau, J., Bloch, P., Schäffer, L., Pettersson, I., Spetzler, J., Kofoed, J., ... & Feigh, M. (2015). Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry, 58(7), 7370-7380. [accessed 15 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., ... & SURMOUNT-1 Investigators. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205-216. [accessed 15 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 15 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 15 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 15 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.